Stock Events

Stock Events

Aldeyra Therapeutics 

$1.5832
64
+$0.03+2.14% 13:33 Today

Statistics

Day High
1.57
Day Low
1.555
52W High
6.18
52W Low
1.07
Volume
34,712
Avg. Volume
-
Mkt Cap
95.51M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

12NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.28
-0.21
-0.13
-0.06
Expected EPS
-0.094
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-33.85MNet Income

Analyst Ratings

2.00Average Price Target
The highest estimate is 2.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
100%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ALDX. It's not an investment recommendation.
Amazon
12
AMZN
Microsoft
10
MSFT
Tesla
10
TSLA
NVIDIA
8
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap128.19B
Vertex Pharmaceuticals is involved in creating treatments for inflammatory and autoimmune diseases, directly competing with Aldeyra's focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals develops therapies for eye diseases, inflammation, and other areas, overlapping with Aldeyra's therapeutic targets.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie works on immunology and inflammatory diseases, competing in the same therapeutic areas as Aldeyra.
AMGEN
AMGN
Mkt Cap224.63B
Amgen focuses on treatments for inflammatory diseases and other serious illnesses, making it a competitor in Aldeyra's market.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences has a portfolio that includes treatments for inflammatory and respiratory diseases, areas Aldeyra is also targeting.
Biogen
BIIB
Mkt Cap31B
Biogen develops therapies for neurological and autoimmune diseases, competing with Aldeyra in the autoimmune space.
Adma Biologics
ADMA
Mkt Cap2.12B
ADMA Biologics is involved in the development of treatments for immune disorders, overlapping with Aldeyra's focus on immune-mediated diseases.
Incyte
INCY
Mkt Cap24.36B
Incyte Corporation focuses on oncology and inflammation, directly competing with Aldeyra in the development of treatments for inflammatory diseases.

About

Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma, and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.
Show more...
CEO
Todd C. Brady
Employees
6
Country
United States
ISIN
US01438T1060
WKN
000A111X8

Listings

STU
DE
137.STU
MU
DE
137.MU
F
DE
137.F
XNAS
US
ALDX

0 Comments

Share your thoughts

FAQ

What is Aldeyra Therapeutics stock price today?▼
The current price of ALDX is $1.58 USD — it has increased by +2.14% in the past 24 hours. Watch Aldeyra Therapeutics stock price performance more closely on the chart.
What is Aldeyra Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Aldeyra Therapeutics stocks are traded under the ticker ALDX.
Is Aldeyra Therapeutics stock price growing?▼
ALDX stock has risen by +1.97% compared to the previous week, the month change is a -8.28% fall, over the last year Aldeyra Therapeutics has showed a -72.32% decrease.
What is Aldeyra Therapeutics market cap?▼
Today Aldeyra Therapeutics has the market capitalization of 95.51M
When is the next Aldeyra Therapeutics earnings date?▼
Aldeyra Therapeutics is going to release the next earnings report on November 12, 2026.
What is Aldeyra Therapeutics revenue for the last year?▼
Aldeyra Therapeutics revenue for the last year amounts to 0 USD.
What is Aldeyra Therapeutics net income for the last year?▼
ALDX net income for the last year is -33.85M USD.
How many employees does Aldeyra Therapeutics have?▼
As of August 19, 2026, the company has 6 employees.
In which sector is Aldeyra Therapeutics located?▼
Aldeyra Therapeutics operates in the Health & Wellness sector.
When did Aldeyra Therapeutics complete a stock split?▼
Aldeyra Therapeutics has not had any recent stock splits.
Where is Aldeyra Therapeutics headquartered?▼
Aldeyra Therapeutics is headquartered in LEXINGTON, United States.